Dublin, Feb. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Biodefense Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
The global biodefense market is projected to grow by $5.41 billion during 2021-2025, progressing at a CAGR of over 7% during the forecast period.
The market is driven by the rising prevalence of infectious diseases and rapid increase in government funding in R&D. The study identifies the growing threat of bioterrorism as one of the prime reasons driving the biodefense market growth during the next few years.
This report provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
The biodefense market is segmented as below:
By Application
- Anthrax
- Smallpox
- Botulism
- Others
By Region
- North America
- Europe
- Asia
- RoW
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biodefense market vendors that include:
- Alexeter Technologies LLC
- Alnylam Pharmaceuticals Inc.
- Altimmune Inc.
- ANP Technologies Inc.
- Bavarian Nordic AS
- Cleveland BioLabs Inc.
- Elusys Therapeutics Inc.
- Emergent BioSolutions Inc.
- General Dynamics Corp.
- GlaxoSmithKline plc
Also, the biodefense market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
For more information about this report visit https://www.researchandmarkets.com/r/3wbkgv
